Related Experiment Videos
[(99m)Tc]MAG(3)-mannosyl-dextran: a receptor-binding radiopharmaceutical for sentinel node detection.
D R Vera1, A M Wallace, C K Hoh
1Department of Radiology, UCSD Cancer Center, University of California, San Diego, School of Medicine, La Jolla, California, USA. dvera@ucsd.edu
Nuclear Medicine and Biology
|August 23, 2001
Summary
Technetium-99m-labeled benzoyl-mercaptoacetylglycylglycyl-glycine-mannosyl-dextran, a novel radiotracer, shows enhanced sentinel lymph node uptake. This receptor-binding agent targets mannose-binding protein on reticuloendothelial tissue.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
- Bioconjugation
Background:
- Reticuloendothelial tissue expresses mannose-binding protein (MBP).
- Developing targeted radiotracers is crucial for diagnostic imaging.
- [(99m)Tc]MAG(3)-mannosyl-dextran targets MBP for receptor-binding.
Purpose of the Study:
- To synthesize and characterize a novel technetium-99m-labeled radiotracer.
- To evaluate the potential of [(99m)Tc]MAG(3)-mannosyl-dextran for sentinel lymph node detection.
Main Methods:
- Synthesis of [(99m)Tc]MAG(3)-mannosyl-dextran using BzMAG(3) and mannose conjugated to dextran.
- Characterization of the macromolecule's size using dynamic light scattering.
- Preliminary sentinel lymph node detection study comparing uptake with Tc-99m sulfur colloid.
Main Results:
- A 19-kDa macromolecule was synthesized with 3 BzMAG(3) and 21 mannose units per dextran.
- Mean diameter of the radiotracer was 5.5 nm.
- [(99m)Tc]MAG(3)-mannosyl-dextran demonstrated greater sentinel lymph node uptake compared to Tc-99m sulfur colloid.
Conclusions:
- [(99m)Tc]MAG(3)-mannosyl-dextran is a viable receptor-binding radiotracer.
- The novel agent shows promise for enhanced sentinel lymph node detection.
- Targeting mannose-binding protein offers a new strategy in nuclear medicine imaging.